Answer
It is licensed for selected adults with Philadelphia chromosome-positive chronic myeloid leukaemia in chronic phase after at least two previous tyrosine kinase inhibitors, provided there is no known T315I mutation.
Sources for this answer
- Scemblix 20 mg and 40 mg film-coated tabletsemc · SmPC Current selected SmPC · Version 8